Benzinga··Vandana SinghAstraZeneca Powers Ahead in COPD with Blockbuster Trial Win, Eyes $3-5B Peak Sales
AstraZeneca's tozorakimab shows positive Phase 3 COPD data, reducing exacerbations versus placebo. Stock rises 3.68% premarket; company forecasts $3-5B peak sales.
SNYAZNREGNmonoclonal antibodyPhase 3 trials